SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-003361
Filing Date
2022-03-10
Accepted
2022-03-10 16:10:05
Documents
43
Period of Report
2022-01-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-20220131.htm   iXBRL 10-Q 1701386
2 EX-31.1 kalv-ex31_1.htm EX-31.1 20830
3 EX-31.2 kalv-ex31_2.htm EX-31.2 17995
4 EX-32.1 kalv-ex32_1.htm EX-32.1 13218
  Complete submission text file 0000950170-22-003361.txt   4752366

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kalv-20220131_lab.xml EX-101.LAB 221828
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kalv-20220131.xsd EX-101.SCH 24395
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kalv-20220131_def.xml EX-101.DEF 47840
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kalv-20220131_pre.xml EX-101.PRE 148134
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kalv-20220131_cal.xml EX-101.CAL 42431
37 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20220131_htm.xml XML 771408
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 22729155
SIC: 2834 Pharmaceutical Preparations